Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
Yeong J, Suteja L, Simoni Y, Lau KW, Tan AC, Li HH, Lim S, Loh JH, Wee FYT, Nerurkar SN, Takano A, Tan EH, Lim TKH, Newell EW, Tan DSW. Yeong J, et al. Among authors: suteja l. J Thorac Oncol. 2021 Aug;16(8):1349-1358. doi: 10.1016/j.jtho.2021.04.016. Epub 2021 May 8. J Thorac Oncol. 2021. PMID: 33975004 Free article.
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
Chua KP, Teng YHF, Tan AC, Takano A, Alvarez JJS, Nahar R, Rohatgi N, Lai GGY, Aung ZW, Yeong JPS, Lim KH, Naeini MM, Kassam I, Jain A, Tan WL, Gogna A, Too CW, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Anantham D, Phua GC, Tan BS, Lee YY, Wang L, Teo ASM, Khng AJ, Lim MJ, Suteja L, Toh CK, Lim WT, Iyer NG, Tam WL, Tan EH, Zhai W, Hillmer AM, Skanderup AJ, Tan DSW. Chua KP, et al. Among authors: suteja l. Clin Cancer Res. 2021 Nov 1;27(21):5939-5950. doi: 10.1158/1078-0432.CCR-20-4607. Epub 2021 Jul 14. Clin Cancer Res. 2021. PMID: 34261696 Free PMC article.
Correction to: Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures.
Teng YHF, Quah HS, Suteja L, Dias JML, Mupo A, Bashford-Rogers RJM, Vassiliou GS, Chua MLK, Tan DSW, Lim DWT, Iyer NG. Teng YHF, et al. Among authors: suteja l. Cancer Immunol Immunother. 2022 Apr;71(4):999. doi: 10.1007/s00262-021-03086-0. Cancer Immunol Immunother. 2022. PMID: 34677648 Free PMC article. No abstract available.
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model.
Liu WN, So WY, Harden SL, Fong SY, Wong MXY, Tan WWS, Tan SY, Ong JKL, Rajarethinam R, Liu M, Cheng JY, Suteja L, Yeong JPS, Iyer NG, Lim DW, Chen Q. Liu WN, et al. Among authors: suteja l. Sci Adv. 2022 Nov 25;8(47):eadd1187. doi: 10.1126/sciadv.add1187. Epub 2022 Nov 23. Sci Adv. 2022. PMID: 36417514 Free PMC article.
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Lim DW, Kao HF, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Wee FY, Jain A, Goh BC, Chua MLK, Liao BC, Ng QS, Hong RL, Ang MK, Yeong JP, Iyer NG. Lim DW, et al. Among authors: suteja l. Nat Commun. 2023 May 15;14(1):2781. doi: 10.1038/s41467-023-38407-7. Nat Commun. 2023. PMID: 37188668 Free PMC article.
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.
Lai GGY, Yeo JC, Jain A, Zhou S, Pang M, Alvarez JJS, Sim NL, Tan AC, Suteja L, Lim TW, Guo YA, Shen M, Saw SPL, Rohatgi N, Yeong JPS, Takano A, Lim KH, Gogna A, Too CW, Da Zhuang K, Tan WL, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Wang L, Toh CK, Lim WT, Tam WL, Tan SH, Skanderup AMJ, Tan EH, Tan DSW. Lai GGY, et al. Among authors: suteja l. JTO Clin Res Rep. 2022 Sep 21;3(12):100416. doi: 10.1016/j.jtocrr.2022.100416. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36426287 Free PMC article.
11 results